Intrexon (XON) Receives Average Rating of “Hold” from Brokerages

Intrexon (NYSE:XON) has received an average recommendation of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $34.67.

XON has been the subject of a number of recent research reports. JPMorgan Chase reaffirmed a “neutral” rating and set a $18.00 price objective (down previously from $22.00) on shares of Intrexon in a research report on Monday, March 5th. ValuEngine downgraded shares of Intrexon from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of Intrexon from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Northland Securities reaffirmed a “buy” rating and set a $17.00 price objective on shares of Intrexon in a research report on Friday, March 2nd. Finally, Bank of America lowered their price objective on shares of Intrexon from $21.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, March 2nd.

How to Become a New Pot Stock Millionaire

Shares of XON traded up $0.35 during midday trading on Wednesday, hitting $17.45. The company had a trading volume of 107,266 shares, compared to its average volume of 1,828,660. The company has a market capitalization of $2,207.03, a P/E ratio of -18.59 and a beta of 1.11. Intrexon has a 52 week low of $10.26 and a 52 week high of $26.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.67 and a current ratio of 1.92.

Intrexon (NYSE:XON) last released its earnings results on Thursday, March 1st. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.08. The company had revenue of $77.03 million during the quarter, compared to the consensus estimate of $48.16 million. Intrexon had a negative net margin of 50.61% and a negative return on equity of 16.94%. The company’s revenue was up 67.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.37) EPS. sell-side analysts expect that Intrexon will post -0.92 earnings per share for the current fiscal year.

In other news, CEO Randal J. Kirk bought 1,000,000 shares of the firm’s stock in a transaction on Friday, January 19th. The stock was purchased at an average price of $12.50 per share, for a total transaction of $12,500,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 56.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of XON. Steward Partners Investment Advisory LLC bought a new position in Intrexon in the 3rd quarter worth about $121,000. Two Sigma Advisers LP bought a new position in Intrexon in the 4th quarter worth about $124,000. Xact Kapitalforvaltning AB bought a new position in Intrexon in the 4th quarter worth about $138,000. SG Americas Securities LLC bought a new position in Intrexon in the 3rd quarter worth about $139,000. Finally, Ellington Management Group LLC bought a new position in Intrexon in the 4th quarter worth about $205,000. Hedge funds and other institutional investors own 75.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3343498/intrexon-xon-receives-average-rating-of-hold-from-brokerages.html.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Dairy Crest  Receives GBX 610 Consensus PT from Analysts
Dairy Crest Receives GBX 610 Consensus PT from Analysts
Brokerages Set NXP Semiconductors  Target Price at $120.50
Brokerages Set NXP Semiconductors Target Price at $120.50
Sientra’s  “Buy” Rating Reiterated at Canaccord Genuity
Sientra’s “Buy” Rating Reiterated at Canaccord Genuity
Sleep Number  Price Target Lowered to $25.00 at Bank of America
Sleep Number Price Target Lowered to $25.00 at Bank of America
ValuEngine Lowers Carrols Restaurant Group  to Sell
ValuEngine Lowers Carrols Restaurant Group to Sell
Synchronoss Technologies  Stock Rating Upgraded by BidaskClub
Synchronoss Technologies Stock Rating Upgraded by BidaskClub


Leave a Reply

© 2006-2018 Ticker Report. Google+.